Chanjo ya MMR ni chanjo hai iliyodhoofishwa inayotoa kinga dhidi ya magonjwa matatu: Surua (Measles), Mabusha (Mumps), na Rubella (German Measles). Chanjo hii inajumuisha virusi hai vilivyodhoofishwa vya magonjwa yote matatu katika sindano moja. Aina kuu ni M-M-R II (Merck) na Priorix (GSK). Surua ni mojawapo ya magonjwa ya kuambukiza zaidi duniani na bado ni sababu kuu ya vifo vya watoto vinavyoweza kuzuiwa kwa chanjo katika Afrika Mashariki. WHO AFRO inafanya kazi ya kuondoa surua na rubella
Chanjo ya MMR ni chanjo hai iliyodhoofishwa inayotoa kinga dhidi ya magonjwa matatu: Surua (Measles), Mabusha (Mumps), na Rubella (German Measles). Chanjo hii inajumuisha virusi hai vilivyodhoofishwa vya magonjwa yote matatu katika sindano moja. Aina kuu ni M-M-R II (Merck) na Priorix (GSK).
Surua ni mojawapo ya magonjwa ya kuambukiza zaidi duniani na bado ni sababu kuu ya vifo vya watoto vinavyoweza kuzuiwa kwa chanjo katika Afrika Mashariki. WHO AFRO inafanya kazi ya kuondoa surua na rubella katika bara la Afrika — lengo ni kufikia kiwango cha chanjo ya ≥95% kwa dozi 2 ya chanjo yenye surua.
Katika mpango wa EPI wa Afrika Mashariki, chanjo ya surua (au MR — surua na rubella) inatolewa kwa watoto wenye umri wa miezi 9 (dozi ya 1) na miezi 18 au miaka 5-6 (dozi ya 2). Tanzania na Kenya zimeingiza chanjo ya MR (measles-rubella) katika EPI, na baadhi ya programu zinatumia MMR kamili.
Rubella ni muhimu hasa kwa sababu ya Congenital Rubella Syndrome (CRS) — maambukizi ya rubella wakati wa ujauzito yanaweza kusababisha kasoro kali za kuzaliwa (uziwi, upofu, kasoro za moyo). Kampeni za chanjo ya MR/MMR zinalenga kuzuia CRS.
Mpango wa EPI (Afrika Mashariki):
Dozi ya 1: miezi 9 za umri (chanjo ya surua au MR)
Dozi ya 2: miezi 18 au miaka 5-6 (kulingana na nchi)
Tanzania: MR kwa miezi 9 na miezi 18; Kenya: MR kwa miezi 9 na miezi 18
Kampeni za nyongeza (SIA — Supplementary Immunization Activities) kwa watoto walioachwa
Watu wazima wasio na chanjo:
Watu wote waliozaliwa baada ya 1957 wanapaswa kuwa na angalau dozi 1 ya MMR
Wahudumu wa afya: dozi 2 za MMR zinapendekezwa sana
Wanawake wa umri wa kuzaa: hakikisha kinga ya rubella kabla ya ujauzito (dozi 1 ya MMR angalau mwezi 1 kabla ya kupata mimba)
Wasafiri:
Wasafiri wote wanapaswa kuwa na chanjo kamili ya surua kabla ya safari
Milipuko ya surua inaendelea katika nchi nyingi — hatari ya kuambukizwa wakati wa safari ipo
Vikundi maalum:
Wanafunzi wa vyuo vikuu — chanjo inahitajika katika nchi nyingi
Wanajeshi — dozi 2 zinapendekezwa
Pregnancy: CONTRAINDICATED — live vaccine.
MMR vaccine is a live attenuated vaccine and is contraindicated during pregnancy.
Women should avoid conception for 4 weeks after MMR vaccination.
Inadvertent vaccination during pregnancy is NOT an indication for termination — no cases of congenital rubella syndrome have been reported following inadvertent vaccination of pregnant women (CDC, WHO).
Pre-conception: check rubella immunity (anti-rubella IgG) and vaccinate non-immune women before pregnancy.
Post-partum: vaccinate rubella-seronegative women before hospital discharge.
Breastfeeding: Safe.
MMR vaccine is safe during breastfeeding. Rubella vaccine virus may be excreted in breast milk and transmitted to the infant, but this does not cause disease and is not a reason to defer vaccination. CDC and WHO recommend post-partum MMR for susceptible breastfeeding mothers.
Pediatric use:
Routine schedule: Dose 1 at 12–15 months, Dose 2 at 4–6 years.
Minimum age: 6 months (for international travel to measles-endemic areas — counts as dose 0; repeat standard 2-dose series from 12 months).
HIV-positive children with CD4 ≥15% should receive MMR (recommendation from WHO and ACIP).
Available as MMR (M-M-R II, Priorix) or MMRV (ProQuad — includes varicella; approved from 12 months to 12 years).
MMRV at dose 1: slightly increased risk of febrile seizures (1 extra per 2,300–2,600 doses) compared to separate MMR + V.
Geriatric use:
Adults born before 1957 are generally considered immune to measles and mumps (through natural infection).
However, serological testing may be warranted for healthcare workers or travelers regardless of birth year.
No upper age limit for MMR vaccination in susceptible adults.
Immune response is adequate in healthy elderly adults. Live vaccine caution applies to severely immunocompromised elderly.
| Kipimo | Siku tangu iliyotangulia | Kipindi cha umri |
|---|---|---|
| Kipimo 1 | — | 1 miaka+ (max: 1 miaka) |
| Kipimo 2 | 1095d | 4 miaka+ (max: 6 miaka) |
Unajua chanjo unayohitaji? Vizuri. Hujui? Tuambie tu unaenda wapi — tutapata chanjo zinazofaa na kliniki. Bure, bila masharti.
Maudhui katika ukurasa huu ni kwa madhumuni ya habari na elimu pekee. Hayaundi ushauri wa kitabibu, utambuzi, au mapendekezo ya matibabu. Ikiwa una wasiwasi wa kiafya, wasiliana na mtaalamu wa afya aliyeidhinishwa. Medova si mtoa huduma za matibabu.
Masharti kamili ya matumizi